These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 11901830)

  • 1. Pharmacogenetics: the Rx perspective.
    Renegar G; Rieser P; Manasco P
    Expert Rev Mol Diagn; 2001 Sep; 1(3):255-63. PubMed ID: 11901830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Family consent and the pursuit of better medicines through genetic research.
    Renegar G; Rieser P; Manasco P
    J Contin Educ Health Prof; 2001; 21(4):265-70. PubMed ID: 11803771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics: the bioethical problem of DNA investment banking.
    Corrigan OP; Williams-Jones B
    Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):550-65. PubMed ID: 16980194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacogenetics in future medical care -- implications for patients and physicians].
    Rogausch A; Brockmöller J; Himmel W
    Gesundheitswesen; 2005 Apr; 67(4):257-63. PubMed ID: 15856385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics in clinical practice: considerations for testing.
    Constable S; Johnson MR; Pirmohamed M
    Expert Rev Mol Diagn; 2006 Mar; 6(2):193-205. PubMed ID: 16512779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global gene mining and the pharmaceutical industry.
    Knudsen LE
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):679-83. PubMed ID: 15979678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics: the Dx perspective.
    Cartwright CP
    Expert Rev Mol Diagn; 2001 Nov; 1(4):371-6. PubMed ID: 11901851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics--legal, ethical and regulatory considerations.
    March R; Cheeseman K; Doherty M
    Pharmacogenomics; 2001 Nov; 2(4):317-27. PubMed ID: 11722282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The origin of informed consent].
    Mallardi V
    Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Contributions of pharmacogenomics to enhance the efficiency of randomized clinical trials].
    de Jesús Castillejos-López M; García-Sancho MC; Torres-Espíndola LM; Pérez-Padilla JR
    Rev Invest Clin; 2006; 58(5):512-24. PubMed ID: 17408112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics in drug discovery and development: a translational perspective.
    Roses AD
    Nat Rev Drug Discov; 2008 Oct; 7(10):807-17. PubMed ID: 18806753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The variation of response to pharmacotherapy: pharmacogenetics--a new perspective to 'the right drug for the right person'.
    Nicol MJ
    Medsurg Nurs; 2003 Aug; 12(4):242-9. PubMed ID: 14515604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consent and privacy in pharmacogenetic testing.
    Robertson JA
    Nat Genet; 2001 Jul; 28(3):207-9. PubMed ID: 11431685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethical and legal implications of pharmacogenomics.
    Rothstein MA; Epps PG
    Nat Rev Genet; 2001 Mar; 2(3):228-31. PubMed ID: 11256075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group.
    Anderson DC; Gomez-Mancilla B; Spear BB; Barnes DM; Cheeseman K; Shaw PM; Friedman J; McCarthy A; Brazell C; Ray SC; McHale D; Hashimoto L; Sandbrink R; Watson ML; Salerno RA; Cohen N; Lister CE;
    Pharmacogenomics J; 2002; 2(5):284-92. PubMed ID: 12439734
    [No Abstract]   [Full Text] [Related]  

  • 17. Ethical, social and legal issues in pharmacogenomics.
    Wertz DC
    Pharmacogenomics J; 2003; 3(4):194-6. PubMed ID: 12931132
    [No Abstract]   [Full Text] [Related]  

  • 18. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification.
    Smart A; Martin P
    Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions.
    Wang L; Weinshilboum R
    Oncogene; 2006 Mar; 25(11):1629-38. PubMed ID: 16550163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomics - therapeutic and ethical issues.
    Patowary S
    Kathmandu Univ Med J (KUMJ); 2005; 3(4):428-30. PubMed ID: 16449851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.